The molecular mechanisms by which bradykinin induces excessive airway obstruction in asthmatics remain unknown. Transforming Growth Factor (TGF-β) has been involved in regulating airway inflammation and remodeling in asthma, although it is not known whether TGF-β can modulate bradykinin-associated bronchial hyper-responsiveness. To test whether TGF-β directly modulates airway smooth muscle (ASM) responsiveness to bradykinin, isolated murine tracheal rings were used to assess whether TGF-β alters ASM contractile responsiveness to bradykinin. Interestingly, we found that TGF-β-treated murine rings (12.5 ng/ml, 18h), exhibited increased expression of B2 receptors, became hyperreactive to bradykinin as shown by increases in the maximal contractile responses and receptor distribution. We investigated the effect of TGF-β on bradykinin-evoked calcium signals since intracellular calcium is a key molecule regulating airway smooth muscle (ASM) excitationcontraction coupling. We reported that TGF-β, in a dose-(0.5 to 10.0ng/ml) and time (2-24h)-dependent manner, increased mRNA and protein expression of the bradykinin 2 (B2) receptor in cultured human ASM cells. Maximal B2 receptor protein expression which co-localized with CD44, a marker of membrane cell surface, occurred after 18h of TGF-β treatment and was further confirmed using fluorescence microscopy. TGF-β (2.5ng/ml, 18h) also increased bradykinin-induced intracellular calcium mobilization in Fura-2 loaded ASM cells. TGF-β-mediated enhancement of calcium mobilization was not attenuated with indomethacin, a cyclooxygenase (COX) inhibitor. These data demonstrated for the first time that TGF-β may play a role in mediating airway hyperresponsiveness to bradykinin seen in asthmatics by enhancing ASM contractile responsiveness to bradykinin, possibly as a result of increased B2 receptor expression and signaling.
Introduction
Asthma is characterized by nonspecific airway hyperresponsiveness (AHR), defined as enhanced contractile response to different agonists that activate G-protein-coupled receptors (GPCR). To date, the molecular mechanisms leading to AHR remain uncertain.
Recent in vitro studies suggested that enhanced contractile properties of airway smooth muscle (ASM), the primary effector tissue regulating bronchomotor tone (reviewed in (10)), are likely one plausible mechanism promoting the excessive bronchoconstriction that characterizes nonspecific AHR in asthma (54) .
Shortening of ASM in response to GPCR stimulation regulates airway caliber and bronchomotor tone by increasing cytosolic Ca 2+ concentrations and subsequent actin-myosin cross-bridge cycling via phosphorylation of myosin light chain (MLC) 20 (8) . Studies using cultured ASM cells from human and other animal models demonstrate that abnormal ASM contractile function may result from simultaneous activation of multiple GPCRs by different agonists or alternatively may be due to increased expression of specific GPCRs and/or by modulation of downstream signaling pathways in ASM such as with the cytokines, TNF-α or IL-1β (48, 53) .
Bradykinin, derived from the kininogen precursor by the action of kallikrein enzymes, is a local-acting blood-born peptide that mediates its effects through two receptors, namely, bradykinin B1 (B1) and B2 (B2) receptors. Although both B1 and B2 receptors contribute to allergen-induced bronchial hyperresponsiveness in rats (35) , in humans, hyperresponsiveness to bradykinin appears to be solely mediated by activation of the B2 receptor and not the B1 receptor (49, 62) . Tao et al. demonstrated increased Ca 2+ responses to bradykinin in ASM cells derived from hyper-responsive inbred rats (55) . Recent studies have shown that
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cytokines such as TNF-α and IL-1β increase bradykinin receptor expression and function in human lung fibroblasts but also in human bronchial ASM cells (48, 53) . Importantly, in subjects with asthma but not in normal subjects, bradykinin induced an excessive airway obstruction (27) . Together, these studies raise the hypothesis that the exaggerated bronchial sensitivity to bradykinin in asthmatics may in part be due to modulation of bradykinin receptor signaling pathways in ASM.
Transforming growth factor-β (TGF-β), a pleiotropic cytokine, plays a role in the pathophysiology of asthma. In subjects with asthma, TGF-β concentrations are higher in the bronchoalveolar fluid as compared with normal subjects (50) . Further, studies suggest that TGF-β promotes airway remodeling and irreversible airway obstruction (14, 17, 39, 51) .
Whether TGF-β regulates AHR by directly modulating ASM contractile function remains unknown. Evidence also suggests that TGF-β potentially reduces ASM relaxation to isoproterenol by decreasing β-adrenergic receptor binding sites in human ASM (45) . Based on the observation that TGF-β and bradykinin levels are increased during chronic airway inflammation and in asthmatic airways (12, 58) , we hypothesized that TGF-β may directly modulate ASM responsiveness to bradykinin.
In this study, we show that TGF-β enhances bradykinin-induced force generation and intracellular calcium signals in ASM by inducing increased cell surface bradykinin B2 receptor expression. This is the first report to demonstrate that TGF-β may participate in bradykinin-induced AHR in asthma by directly altering ASM contractile function. Further characterization of the precise pathways by which TGF-β modulates ASM function may provide opportunities for new therapeutic approaches in the regulation of AHR in asthma.

MATERIALS AND METHODS
Measurement of isometric force generation
Isometric force generation by murine cultured tracheal rings was performed as described previously (19) . Briefly, mouse tracheae obtained from 7-to 12-wk-old Balb/c mice (Charles River Laboratories, Wilmington, MA) were sectioned into 3-4 mm long segments. The tracheal rings were then cultured overnight in Ham's F-12 medium supplemented with 100 mM HEPES, 1.0 M NaOH, 10% fetal bovine serum (Hy-Clone, Logan, UT), 0.2 M glutamine, 1.0 M CaCl 2 , 100 U/ml penicillin, and 100 µg/ml streptomycin. The organ cultures were treated with 12.5ng/ml TGF-β or diluent alone for 18 hrs and then washed with K-H solution containing (in mM) 118 NaCl, 4. with an MP 100WS system (BIOPAC Systems Inc., Santa Barbara, CA). All initial tensions of tracheal rings were set at approximately 0.5 g. After a 45 minute equilibration period, cumulative concentration-isometric force curves were then generated to bradykinin (1 nM to 30 mM). After three washings with 10 mls of K-H Buffer, the tracheae were contracted with 100 mM KCl.
Human and murine ASM cell culture
Human tracheae were obtained from lung transplant donors in accordance with procedures approved by the University of Pennsylvania Committee on Studies Involving Human Beings
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at the University of Pennsylvania. Trachealis muscle was enzymatically dissociated using 640 U/ml collagenase and 10 U/ml elastase, in the presence of 1 mg/ml soybean trypsin inhibitor and 0. Murine tracheal smooth muscle cells were cultured from explants of excised tracheas using a modification of previously described methods (28, 44) . The entire trachea between the larynx and main stem bronchi was removed and placed in a sterile Petri dish containing cold PBS. After additional surrounding tissue and epithelium was removed with the aid of a dissecting microscope, myocytes were dispersed from dissected trachealis using 10 U/ml elastase and 600 U/ml collagenase. Myocytes were seeded and grown on fibronectin-coated plastic culture plates in Ham's F-12 medium supplemented with 10% FBS, 2 mM glutamine, 100 U/ml penicillin, 100 µg/ml streptomycin, 2.5 µg/ml fungizone, 10 μg/ml EGF, and 10 μg/ml PDGF. The explants were incubated at 37 °C in a humidified environment of 95% air, 5% CO 2 . Once the monolayer became confluent, the cells were harvested by trypsinization and passaged into 100 mm tissue culture plates at a 1:4 ratio. Greater than 90% of these cells, as determined by immunohistochemistry, expressed smooth muscle α-actin. All experiments were performed on confluent cells at matched passage numbers 2-4.
Treatment of human ASM with cytokines and/or antagonists
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Confluent human ASM cells were growth-arrested by incubating in serum-free Ham's F12 with 0.1% BSA for 48 hrs before stimulating them with TGF-β (2.5 ng/ml). In some experiments, human ASM were pre-treated with indomethacin (2 μM) for 30 min before treating with TGF-β.
Characterization of bradykinin receptor expression
RT-PCR analysis was performed as described previously (16 Western blot analysis was performed as described previously (4) . Briefly, human ASM cells were washed with cold phosphate-buffered saline and lysed in buffer containing 10 
Measurement of intracellular calcium concentration
Fura-2/AM, a cell permeant, ratiometric calcium indicator dye was used to determine the intracellular calcium concentration in human ASM cells. Calcium measurements were determined as described previously (21) . Briefly, human ASM cells grown on 100mm dishes were washed with HBSS containing 10 mM N-2-hydroxyethylpiperazine-N'-ethane sulfonic acid, 11 mM glucose, 2.5 mM CaCl 2 , and 1.2 mM MgCl 2 (pH 7.4) and incubated with 5 µM
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fura-2/AM for 30 min at 37°C and 5% CO 2 . Fura-2-loaded cells were trypsinized, and fluorescence was estimated in cell suspensions by excitation at 340 and 380 nm wavelengths.
Fluorescence emissions were collected separately for each wavelength at 510-nm using a spectrofluorimeter (Photon Technology International Inc., Lawrenceville, NJ). The ratio of fluorescence intensities at 340 and 380 nm wavelength was determined and converted to the calcium concentrations using the standard equation (21) . The net calcium responses to contractile agonists were calculated by subtracting the basal from that of the peak intracellular calcium concentration. All experiments were performed at 37°C.
Immunolocalization of B2 Receptor on Human ASM Cells
Human ASM cells were serum-starved for 48 hrs and stimulated with diluent-control or TGF-β (2.5 ng/ml) on 2-well slides (Nunc, Naperville, IL). Slides were first fixed with 4%
formaldehyde and then permeabilized with a mixture of cold acetone/methanol solution (vol/vol) for 10 min. After washing with PBS, the cells were exposed to 5 % BSA in PBS for 60 min. at 37°C and incubated with 4 µg/ml anti-bradykinin B2 receptor Ab (Affinity Bioreagents, Golden, CO) or isotype-matched control (polyclonal rabbit IgG) in 5% BSA in PBS for 60 min. at 37°C, washed with PBS followed by incubation with goat anti-rabbit IgG F(ab') 2 Alexa 488 (Molecular Probes). Co-localization of bradykinin B2 receptor at the cell surface was demonstrated by using the cell surface glycoprotein receptor, CD44. Hermes-3, a monoclonal antibody against an extracellular epitope to the cell surface glycoprotein, CD44, at a concentration of 4 μg/ml was used as cell membrane marker (37) . Mouse IgG2a antibody at the same concentration was used as the isotype matched negative control for Hermes-3.
Alexa 594-conjugated goat anti-mouse antibody was used as the secondary antibody (1:400 dilution, Molecular Probes). Nuclei were counter-stained with DAPI. Slides were then
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washed with PBS and then mounted with anti-fade agent. Slides were viewed on an Olympus I-70 inverted fluorescent microscope. Fluorescence images were captured using a Hamamatsu 12-bit coupled-charged device camera. Image processing was performed using IMAGE 1 software (Universal Imaging, West Chester, PA).
Statistical Methods
Tension was calculated as milligram tension per milligram tracheal smooth muscle weight (mg/mg). The concentrations of agonists required to produce half-maximal contraction (EC 50 ) were determined, and the EC 50 of bradykinin were then converted to log values.
Concentration of agonists required to produce a half-maximal relaxation (pD 2 ) was determined with -log values of the EC 50 . All values were expressed as means ± SE.
Comparisons among groups with or without TNF-α were performed by a one-way ANOVA.
Student's unpaired t-test was used to compare the effect of drug treatment. A P value of <0.05 was considered significant.
Reagents
Tissue culture reagents and primers used for PCR were obtained from Invitrogen (Carlsbad, CA). Recombinant human TGF-β was purchased from R&D Systems (Indianapolis, IN).
Carbachol, bradykinin, and Fura 2/AM were purchased from Sigma (St Louis, MO). Hermes-3 antibody was prepared from hybridoma supernatant. Mouse IgG2a antibody was purchased from Jackson Immuno Labs (West Grove, PA).
.
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RESULTS
TGF-β augments bradykinin-induced isometric force generation in murine cultured tracheal rings.
We have previously shown that cytokines such as TNFα modulates ASM contractile response to GPCR activation using an organ culture model (19) . In this study, we used isolated murine tracheal rings to determine whether TGF-β promotes ASM hyperresponsive to bradykinin. In a concentration-dependent manner, bradykinin evoked isometric force generation in murine tracheal rings, demonstrating that ex vivo tracheal rings retain contractile properties to bradykinin ( Figure 1A ). Maximal bradykinin-induced force generation represents approximately 30% of a maximal methacholine-induced response (data not shown).
To determine whether TGF-β modulates agonist-induced force generation, murine tracheal rings were cultured in the presence and absence of 12.5 ng/ml TGF-β for 18 hours. In previous experiments, we determined that a minimum of 8-18 hours of incubation was needed for cytokine-mediated effects (19) . We and others have also shown that concentrations of recombinant human cytokines in the 0.1 to 10 nM range, consistent with the in vitro and ex vivo doses used in this study, are often required when treating murine tracheal rings as compared to cultured cell systems (1, 3, 57, 62) . This is likely secondary to diffusional barriers in tracheal tissue. In TGF-β-treated murine tracheal rings, there was a significant enhancement of the bradykinin-induced contractile response, at concentrations ranging from 
TGF-β increases B2 receptor mRNA and protein expression in a time-dependent manner.
Since the effect of TGF-β on bradykinin-mediated calcium mobilization was not inhibited by COX inhibitors, we next examined the effect of TGF-β in regulating bradykinin receptor gene expression. As shown in Figure 5A , TGF-β induced a time-dependent increase in B2 receptor mRNA levels in human ASM. Surprisingly, B1 receptor mRNA levels did not change significantly. At 18 hours of treatment of human ASM with 2.5ng/ml of TGF-β, the relative amount of B2 receptor mRNA was approximately double as compared with B2 mRNA from diluent-treated cells when normalized to β-actin. In Figure 5B , TGF-β treatment for 18 hrs
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induced an increase in B2 receptor mRNA levels in murine tracheal rings compared to basal levels of B2 receptor mRNA.
To determine whether B2 receptor protein expression is also increased by TGF-β, human ASM monolayers were treated with TGF-β for varying times and doses. As shown in Figure 6A and 6B, TGF-β markedly increased B2 receptor expression, in a dose-and timedependent manner with maximal B2 receptor levels detected by immunoblot at a concentration of 2 ng/ml. Optimal B2 expression was seen after 17h of treatment with TGF-β. Collectively, these data suggest that TGF-β enhances expression of bradykinin receptors, promoting ASM calcium mobilization and force generation to bradykinin.
TGF-β increases B2 receptor expression on human ASM cells. Immunocytochemistry, using
an antibody that recognizes a portion of the intracellular C-terminus, was used to further investigate the protein expression of the bradykinin B2 receptor on HASM. As shown in Figure 7 , immunocytochemical analysis revealed that there is a basal expression of B2 receptor that is significantly increased at the cell surface after 24 hour stimulation with TGF-β (2.5 ng/ml). To confirm these results, we localized bradykinin B2 receptor expression in human ASM cells to the cell surface after TGF-β treatment using double immunofluorescent staining. Using the monoclonal antibody, Hermes-3, which binds the extracellular epitome of CD44, a receptor that is highly expressed on the cell surface (11), it was possible to demonstrate an increase in co-localization of the B2 receptor at the cell surface after TGF-β (2.5 ng/ml) treatment compared to vehicle control treatment ( Figure 7C and 7D ). An enhancement of co-localization of B2 receptor and CD44, a cell surface marker highly expressed on ASM (42) , was demonstrated by merged imaging. No immunostaining was
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observed with isotype matched controls, demonstrating the specificity of the analysis. These results suggest that TGF-β treatment results an in increase in cell surface expression of bradykinin B2 receptor on human ASM cells.
DISCUSSION
In this study, we investigated whether TGF-β, a cytokine found to be elevated in asthmatic airways (58) , modulates ASM responsiveness to bradykinin, a GPCR agonist known to induce bronchoconstriction in subjects with asthma but not in healthy volunteers.
We, and others, have shown that "pro-asthmatic" mediators, such as TNF-α, prime ASM cells to become non-specifically hyperresponsive to different contractile agonists including bradykinin (7, 8, 19, 29, 31, 56) . ] i to bradykinin, a higher dose concentration of bradykinin (10 nM) was required in murine ASM cells. This may be due to species-dependent differences in bradykinin receptor expression and affinity (32) .
Differences between murine and human airway responsiveness to bradykinin have been described by others. Bradykinin is a potent bronchoconstrictor of human airways in vivo (27) while the effects of bradykinin are negligible in isolated murine airways (62) . These results
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indicate that TGF-β enhances ASM responsiveness to bradykinin, possibly via increased calcium signals in part at least due to transcriptional induction of B2 receptor in ASM cells.
The molecular mechanisms promoting airway hyperresponsiveness, a key feature of asthma, remain unknown. Dysfunction of ASM, the main effector tissue regulating bonchomotor tone, has been considered a plausible mechanism leading to AHR (reviewed in (6)). Data obtained using isolated airway preparations as an ex vivo model support the concept that "pro-asthmatic" conditions can contribute to the development of AHR by enhancing ASM responsiveness to contractile agonists (reviewed in (8, 31, 43) ). Using cultured murine tracheal rings, previous reports have demonstrated that "pro-asthmatic" cytokines, TNF-α and IL-13, induce non-specific ASM hyperresponsiveness to different agonists including bradykinin, serotonin or carbachol (19, 56, 62) . Interestingly, we also reported that these cytokines directly modulate ASM cell function via enhancement of GPCRassociated calcium transients, the activating signal that initiates ASM shortening and contraction (7, 38) .
We now show that murine tracheal rings treated with TGF-β have significantly increased contractile responses to bradykinin, when compared to diluent-treated tracheal rings that show modest contractile responses to bradykinin. While TGF-β is an important fibrinogenic and immunomodulatory molecule promoting airway remodeling in asthma (reviewed in (23)), our study is the first to suggest a potential direct role of TGF-β in promoting AHR to bradykinin, a feature described in subjects with asthma (49) . The unique finding that TGF-β has little effect on carbachol-evoked calcium responses also contrasts with the non-specific effects of other cytokines, including TNF-α and IL-13, which enhanced GPCR-associated calcium responses to bradykinin, carbachol and thrombin (3, 5, 9, 36, 47) .
The selective effect of TGF-β is confirmed with a sub-optimal dose of carbachol as well as at a higher dose. TGF-β appears to have little effect on carbachol-evoked calcium response at 1 μM or at 10 μM doses of carbachol. Although beyond the scope of this study, the selective ability of TGF-β to enhance bradykinin-induced, but not carbachol-induced, calcium response may be regulated by differences in muscarinic receptor expression on ASM.
Previous studies showing that ASM express a family of TGF-β receptors, TβR I, showed that TGF-β can induce bradykinin B2 receptor mRNA expression in both murine tracheal rings and human ASM cells. Evidence suggests that other "pro-asthmatic" cytokines including IL-13 or TNF-α can also increase B2 receptor density in ASM cells or murine tracheal rings (33, 53, 62) , however TGF-β appears to be more agonist selective. Here, we found that in our ex vivo model, i.e. TGF-β-treated murine tracheal rings, levels of B2 receptor were significantly increased compared to controls, further supporting the hypothesis that the increased ASM responsiveness to bradykinin induced by TGF-β may involve a modulation of B2 receptor expression. Other studies showed that TGF-β-induced reduction in β 2 -adrenoreceptor expression can also serve as a "pro-contractile" mechanism by decreasing β 2 -adrenoreceptor function, and reducing protein kinase A-mediated ASM relaxation (13, 45) .
While our study does not directly address the molecular mechanism behind B2 receptor gene expression, our data support other reports that B2 receptor mRNA levels are enhanced via multiple mechanisms including increases in the rate of gene transcription, increases in the mRNA stability (52) It should also be noted that TGF-β likely plays a complex regulatory role with some of its effects on ASM being concentration-dependent. In Figure 6 , we demonstrate a significant increase in B2 receptor expression on ASM at lower doses of TGF-β, e.g., 1-5 ng/ml, while higher concentrations of TGF-β appear to have only a modest effect. This concentrationdependent physiologic regulation by TGF-β has been reported in several other cell systems as well as ASM. TGF-β has been shown to release a peak concentration of prostaglandin E2 at 1 ng/ml and less release at 10 ng/ml (25) . Similar to the biphasic pattern we see with B2
receptor expression in human ASM, Cysteinyl leukotriene 1 receptor (CysLT1R) also is induced in a concentration-dependent manner with increasing doses of TGF-β and at doses greater than 10 ng/ml, CysLT1R significantly decreases (24) . TGF-β has been demonstrated to have opposing effects on proliferation at low versus high concentrations with higher concentrations inhibiting proliferation in lung fibroblasts (63) .
In summary, we show that murine tracheal smooth muscle and human ASM cells treated with TGF-β demonstrate increased ASM responsiveness specifically to bradykinin, an effect that possibly involves increased expression and function the bradykinin B2 receptor.
Thus, the direct effect of TGF-β on ASM responsiveness to bradykinin likely plays a significant role in promoting bronchoconstriction in response to bradykinin seen in asthma and potentially other airway diseases characterized by inflammation.
LCMP-00027-2005 Cumulative concentration-response curves to BK were measured in cultured murine rings in the absence (◊, n= 6) or in the presence of 12.5ng/ml TGF-β (■, n=6) as described in Materials and Methods. All tension measurements from groups were expressed as mean ± SE. *P<0.05 compared with rings treated with diluent alone. ng/ml) for up to 24 hrs, was subjected to RT-PCR with the primers for β-actin, B2 receptor, and B1 receptor as described in Materials and Methods. B: Murine RNA (500 ng), processed from murine tracheal rings which were treated with TGF-β (12.5ng/ml) for 18 hrs, was subjected to RT-PCR with primers for GAPDH and B2 receptor. PCR products were separated on 1.5% agarose gel and stained with ethidium bromide. In a time dependent manner, TGF-β increased bradykinin B2 receptor RNA without increasing B1 receptor RNA in human ASM. TGF-β treatment for 18 hrs increased bradykinin B2 receptor RNA in murine trachea compared to trachea that were not treated with TGF-β. 
